

# US PATENT & TRADEMARK OFFICE

## PATENT APPLICATION FULL TEXT AND IMAGE DATABASE



( 1 of 1 )

**United States Patent Application****20030100029****Kind Code****A1****Stout, Robert L. ; et al.****May 29, 2003****Methods of determining active levels of drugs in fluid samples**

### Abstract

Methods for determining the presence and level of active drugs in fluid samples are provided. Advantageously, entire families or classes of drugs can be tested for in one test by identifying the enzyme or receptor upon which members of that drug family act and measuring enzyme activity levels or binding activity levels of receptors. Methods for establishing standard activity levels of these drugs based upon results from samples having known quantities of drug therein are also provided.

**Inventors:** **Stout, Robert L.; (Overland Park, KS) ; Chien, Sue Min; (Lenexa, KS) ; Dunham, Steve H.; (Kansas City, MO)**

**Correspondence Name and Address:** **HOVEY, WILLIAMS, TIMMONS & COLLINS  
SUITE 400  
2405 GRAND BLVD.  
KANSAS CITY  
MO  
64108  
US**

**Assignee Name and Address:** **Clinical Reference Laboratory**

**Serial No.:** **037772**

**Series Code:** **10**

**Filed:** **November 9, 2001**

**U.S. Current Class:**

**435/7.9**

**U.S. Class at Publication:**

**435/7.9**

**Intern'l Class:**

**G01N 033/53; G01N 033/542**

### Claims

We claim:

1. A method of determining the presence of an active drug in a fluid sample, said drug in its active state capable of modifying the activity level of an enzyme on a selected substrate, said method comprising the steps of: providing a first fluid sample, said sample including said enzyme; adding a quantity of said selected substrate to said first fluid sample; measuring the activity level of said enzyme on said selected substrate; and determining the presence of said active drug by said measured activity level.
2. The method of claim 1 further comprising the step of comparing said measured activity level with a standard activity level.
3. The method of claim 2, said standard activity level representing the activity level of said enzyme on a known quantity of said selected substrate.
4. The method of claim 1 further comprising the step of correlating said measured activity level with the concentration of said active drug.
5. The method of claim 4, said correlating step including the step of comparing said measured activity level with a standard activity level.
6. The method of claim 5, said standard activity level representing the activity level of said enzyme on a known quantity of said selected substrate.
7. The method of claim 1, said enzyme activity level decreasing when said active drug is present.
8. The method of claim 1, said enzyme activity level increasing as the level of active drug in said sample decreases.
9. The method of claim 1, said enzyme activity level decreasing as the level of said active drug in said sample increases.
10. The method of claim 1, said drug being selected from the group consisting of ACE-inhibiting drugs.
11. A method of determining standard enzyme activity levels on a selected substrate comprising the steps of: providing a sample containing said enzyme; adding a known quantity of said selected substrate to said sample; measuring the activity level of said enzymes on said selected substrate; and using said measured activity level as said enzyme's standard activity level for said known quantity of selected substrate.
12. A method of determining the presence of active ACE-inhibiting drugs present in a fluid sample, said ACE-inhibiting drugs in their active state being capable of modifying the activity level of a target enzyme on a selected substrate, said method comprising the steps of: providing a first fluid sample; adding a quantity of said selected substrate to said first fluid sample; and determining the activity level of said target enzyme on said selected substrate in said fluid sample at a first time to provide a base line activity level.
13. The method of claim 12, further including the step of comparing said base line activity level with a standard activity level to determine the concentration of said active ACE-inhibiting drugs in said first fluid sample.
14. The method of claim 12, further including the step of determining the activity level of said target enzyme on said selected substrate in said fluid sample at a second time to provide a first activity level, said second time occurring after said first time.
15. The method of claim 14, further including the step of comparing said base line activity level with said first activity level.

16. The method of claim 14, further including the step of comparing said first activity level with a standard activity level.

17. The method of claim 12, further including the steps of: providing a second fluid sample; adding a quantity of said selected substrate to said second fluid sample; and determining the activity level of said target enzyme on said selected substrate in said second fluid sample to provide a second activity level.

18. The method of claim 17, further including the step of comparing said first activity level with said second activity level.

19. The method of claim 12, said first fluid sample comprising urine.

20. The method of claim 12, said base line level of activity being representative of said target enzyme's activity when no ACE-inhibiting drugs are present.

21. The method of claim 12, said base line level of activity being correlated with a known standard of active ACE-inhibiting drug concentration.

22. The method of claim 12, said ACE-inhibiting drugs being selected from the group consisting of benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril, ramipril, and trandolapril and combinations thereof.

23. The method of claim 12, said determining step including the step of measuring the optical density of said fluid sample.

24. The method of claim 12, said activity levels being correlated with the optical density at 340 nm.

25. A method of determining the presence of active beta-blocking drugs in a fluid sample, comprising the steps of: providing a first fluid sample, said fluid sample containing a target ligand operable for binding to a specific receptor; and assaying said sample for the presence of said active beta-blocking drug.

26. The method of claim 25, said assaying step comprising the steps of: adding a quantity of labeled ligand to said fluid sample, said labeled ligand operable for binding to said specific receptor; and contacting said fluid sample containing said target ligand and said labeled ligand with a membrane expressing said specific receptor.

27. The method of claim 25, further comprising the step of determining the concentration of active beta-blocking drugs in said fluid sample.

28. The method of claim 27, further including the step of comparing said determined concentration of active beta-blocking drugs with a known standard of active beta-blocking drug concentration.

29. The method of claim 28, said known standard of active beta-blocking drug concentration being correlated with the concentration of active beta-blocking drugs present in said fluid after a known dosage of beta-blocking drugs is taken by a patient.

30. The method of claim 29, further comprising the step of determining if a patient is taking a prescribed dosage of beta-blocking drugs by comparing said determined concentration with said known dosage.

31. The method of claim 25, said fluid sample comprising urine.

32. The method of claim 28, said known standard being representative of said assay result when no beta-blocking drugs are present.

33. The method of claim 27, said specific receptor being selected from the group consisting of beta-adrenergic receptors.

34. The method of claim 33, said specific receptor being a B1 adrenergic receptor.

35. The method of claim 27, said determined concentration being correlated with a known standard of active beta-blocking drug concentration.

36. The method of claim 25, said beta-blocking drug being selected from the group consisting of atenolol, propranolol, metoprolol, nadolol, pindolol, timolol, carvedilol, and sotalol and combinations thereof.

37. The method of claim 27, said determining step including the steps of: contacting said sample with a receptor specific for beta-blockers and a labeled drug, said drug operable for indicating an interaction between said labeled drug and said determined drug with said receptor.

38. A method of determining the presence of active ACE-inhibiting drugs or the active metabolites thereof in a fluid sample, said method comprising the steps of: obtaining a fluid sample; and detecting ACE-inhibiting drugs in said sample using an assay capable of detecting said ACE-inhibiting drugs or said active metabolites thereof.

39. The method of claim 38, said ACE-inhibiting drugs being selected from the group consisting of benazepril, captopril, enalapril, fosinopril, lisinopril, quinopril, ramipril, and trandolapril or combinations thereof.

40. The method of claim 38, said fluid sample comprising urine.

41. A method of determining the presence of an active drug in a fluid sample, said drug in its active state capable of binding with a selected receptor and inhibiting binding of a target ligand to said receptor, said method comprising the steps of: providing a first fluid sample, said sample including said receptor; adding a quantity of said target ligand to said first fluid sample; measuring the binding activity level of said ligand to said receptor; and determining the presence of said active drug by said measured binding activity level.

42. The method of claim 41 further comprising the step of comparing said measured binding activity level with a standard binding activity level.

43. The method of claim 42, said standard binding activity level representing the binding activity level of said receptor with a known quantity of said target ligand.

44. The method of claim 40 further comprising the step of correlating said measured binding activity level with the concentration of said active drug.

45. The method of claim 44, said correlating step including the step of comparing said measured binding activity level with a standard binding activity level.

46. The method of claim 45, said standard binding activity level representing the binding activity level of said receptor with a known quantity of said target ligand.

47. The method of claim 41, said measured binding activity level decreasing when said active drug is present.

48. The method of claim 41, said measured binding activity level increasing as the level of active drug in said sample decreases.

49. The method of claim 41, said measured binding activity level being inversely proportional to the level of said active drug in said sample.

50. The method of claim 41, said drug being selected from the group consisting of beta-blocking drugs.

---

### *Description*

---

## BACKGROUND OF THE INVENTION

### [0001] 1. Field of the Invention

[0002] The present invention is concerned with the screening for the presence of drugs in fluid samples. More particularly, the present invention is concerned with screening for the presence of drugs in fluid samples which may or may not contain any drugs being screened for. Still more particularly, the present invention is concerned with the screening for the presence of drugs in fluid samples when it is known that the individual providing the fluid sample is on drugs and the screening procedure can help determine proper medication levels. In the instance where it is not known whether or not the individual providing the sample is on any drugs, the present invention is particularly useful in that it identifies the presence of drug families rather than discreet drugs. The same is true for when it is known that the individual providing the sample is supposed to be on a drug that is in a particular family of drugs whereby the screening procedures can be used to determine compliance with taking prescribed medications. Even more particularly, the present invention utilizes a screening technique which identifies the presence of at least one member of a family of drugs by the effects of the drugs on specific enzymes or receptors which are acted upon by the specific families of drugs.

### [0003] 2. Description of the Prior Art

[0004] The laboratory screening of drugs, both prescription and non-prescription, is typically by a form of immunodetection which relies on the development of a specific antibody to the drug or compound being screened for. This antibody is then used to detect the drug in a sample which may or may not contain the drug or compound of interest. A major hurdle which needs to be overcome to accomplish immunodetection using this method is the development of an antibody that is specific for each drug. The antibody must be produced with a sufficient titer, a measure of concentration, to efficiently detect the presence of the drug. Additionally, the antibody must have sufficient specificity to react only with the drug of interest so that accurate results may be obtained. While these requirements are normally obtainable, they inherently result in a system with severe limitations. The greatest of these limitations is the detection of the drug after it is no longer biologically active.

[0005] Drugs may be broadly classified into one of two categories. The first type of drug is active in the form that is present in the drug as taken by an individual. This category of drugs requires no structural modification and the drugs in this class are therapeutically active in the medication. The second category of drugs requires a structural change before becoming therapeutically active. In both categories, additional metabolites may also be as active as the parent compound or its first metabolite while other metabolites may have little or no activity. This drastically increases the difficulty in determining the amount of therapeutically active drug present in any fluid sample taken from an individual. Due to the similarity of metabolite structures with the drug as taken or with other metabolites, the metabolites may also contribute to the immunodetection signal so that, regardless of prodrug or metabolite, the signal would be related to total drug exposure. In some instances a metabolite may be therapeutically inactive while still being detected by the antibody developed to detect the drug. In this scenario, immunological detection would overestimate the concentration of active drug present. The opposite problem may occur where a detected metabolite has an even greater activity than the parent drug. In this scenario, immunological detection would underestimate the concentration of active drug present. Thus, current immunodetection methods cannot differentiate the

biological activity of the drug or its metabolites. The result is a system which is good at detection of the presence of a drug but totally ineffective at the more important determination of the amount of active drug present. Moreover, metabolites which are similar in structure, regardless of their activity level, may also be identified and thereby further contribute to an inaccurate determination of the concentration of active drug present in the sample tested. Accordingly, one thing needed in the art is a drug screening test which only determines or detects the presence or levels of active drugs in fluid samples.

[0006] Many drugs and classes of drugs produce their effect by activational inhibition of specific receptors or activation or inhibition of specific enzymes. Often, an entire class of drugs will produce the same effect on a specific receptor or enzyme, thereby resulting in the therapeutic effect. In the case of drugs and classes of drugs effecting receptors, a drug may bind to a receptor site, thereby inhibiting the binding of the natural activators or inhibitors. Alternatively, the drug may react in the receptor site and irreversibly modify the structure or shape of the receptor, thereby resulting in its inactivation. Other methods of inhibition include binding to other regulatory sites present on the receptor, interfering with cofactor binding, or interaction with other cell surface molecules required for receptor action. Irrespective of the method of inactivation or inhibition, the receptor no longer works with its normal efficiency. Accordingly, another thing needed in the art is a drug screening test which identifies drug presence by determining effects on specific receptors. The usefulness of such a test could be greatly increased if the test could identify the presence of a class of drugs regardless of which specific drug in that class was actually present.

[0007] In the case of drugs which effect the activation or inhibition of specific enzymes, a drug may bind to an enzyme's catalytic site and inhibit the binding of the natural substrate. Alternatively, the drug may react in the catalytic site and irreversibly modify the enzyme, thereby resulting in its inactivation. Other methods of inhibition include binding to the regulatory sites present on the enzyme, interfering with cofactor binding, or interaction with the normal substrate, thereby limiting its binding to the enzyme. Irrespective of the method of inactivation or inhibition, the enzyme no longer works with its normal efficiency. In reality, the drug and/or its metabolites have reduced the enzyme's catalytic rate. Therefore, another thing needed in the art is a drug screening test which identifies drug presence by determining enzyme activity. Again, the usefulness of such a test could be greatly increased if the test could identify the presence of an entire class of drugs, regardless of which specific drug in that class was actually present.

## SUMMARY OF THE INVENTION

[0008] The present invention provides a novel approach for determining the presence of drugs in fluid samples. Advantageously, entire families of drugs are identified using the present invention so that one test can provide information on what type of drug is present in a fluid sample. The methods are based on the effects an active drug has on either a target enzyme or a receptor. In the case of drugs which exert their effects on enzymes, the enzymes may be activated or inhibited by the drug binding to the enzyme's catalytic site, thereby inhibiting the binding of the natural substrate. Captopril is a good example of a drug that exhibits this type of competitive inhibition. Captopril is a member of the drug family or class known as Angiotensin Converting Enzyme (ACE) inhibitors which includes the drugs benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril, moexipril, ramipril, and trandolapril. This class or family of drugs assists in regulating blood pressure by inhibiting the conversion of angiotensin I to angiotensin II which is a powerful vasoconstrictor that helps regulate blood pressure, renal blood flow, and blood volume. If there is an excess amount of angiotensin II, which can be caused by the enzymatic action of ACE, blood pressure increases. ACE inhibiting drugs prevent the cleavage of angiotensin I to angiotensin II, thereby reducing blood pressure.

[0009] As noted above, the laboratory screening of drugs is typically by a form of immunodetection. In the case of the ACE inhibiting class of drugs, different antibodies must be developed for nearly every drug as the members of this drug class have dissimilar structures. Additionally, most ACE inhibiting drugs have metabolites that also demonstrate varying degrees of activity and, due to structural similarities, many of these metabolites will be detected, regardless of their activity level, using an antibody-based approach. Thus, when screening for use of this type of drug, one must first know which specific ACE inhibitor is being

used and any results may include a number of false positives which occur when metabolites which are inactive or have low activity are identified by the antibody, and thereby contribute to a determination that the sample tested is positive for the drug. Such a test does not really provide the needed information of how much active drug is present in a patient's system. If the specific drug is not known, a number of different tests may have to be run until the specific drug is identified.

[0010] However, because all members of the ACE-inhibiting drug family act on the same enzyme, the present invention can be used for the detection of the entire family. Advantageously, the active metabolites will also be identified, thereby providing results of the amount of active drug present in a patient's system. Thus, the invention may be used to screen samples for the presence of a class of drugs including their active metabolites. It may also be used to monitor patient compliance or to determine why one drug appears to be more effective in a particular patient. Finally, the present invention will be useful in emergency type situations where it is necessary to quickly ascertain what types of drugs a patient is on, thereby potentially avoiding dangerous drug interactions or needless dosing of additional medications.

[0011] The present invention is also useful in screening for the presence of drugs or families of drugs which exert their effects by reacting in an enzyme's catalytic site, irreversibly modifying and inactivating the enzyme, binding to other regulatory sites present on the enzyme, interfering with cofactor binding, or interaction with the normal substrate and limiting its binding to the enzyme.

[0012] To test for the presence of a drug or class of drugs, a sample of fluid is obtained from a patient. The substrate upon which the enzyme acts is then added to the sample and the activity of the enzyme is determined. If the activity of the enzyme is reduced in comparison to a control sample having no drug present, the sample is deemed positive for that class of drugs. Preferably, a set of standards will be set up using methods of the present invention. These standards would be established by testing samples that have a known quantity of active drug present. Results from such controlled testing could then be used comparatively to determine drug presence and levels in samples having unknown amounts of drug present.

[0013] Other classes of drugs exert their effects on specific receptors and therefore can also be identified by using methods of the present invention. The family of drugs commonly called the "beta-blockers," which includes the drugs atenolol, propranolol, metoprolol, nadolol, pindolol, timolol, carvedilol, and sotalol, are an example of this class of drug. Members of this class or family of drugs act as competitive antagonists at the adrenergic beta receptors and reduce the symptoms connected with hypertension, cardiac arrhythmias, migraine headaches, and other disorders related to the sympathetic nervous system. Adrenergic receptors form the interface between the nerves that serve the heart, blood vessels and kidneys and the organs themselves. Catecholamines such as norepinephrine and dopamine are released from sympathetic nerve terminals and bind to adrenergic receptors on the surface of target cells, thereby activating receptors, which modify the functions of these cells. Beta-blocking drugs reduce receptor occupancy by catecholamines and other beta agonists by competitively binding to these receptors. Adrenaline (also known as epinephrine) is classified as a catecholamine hormone and it is mainly the effects of adrenaline on the body's beta-receptors that are blocked by beta-blockers.

[0014] Again, because one test can identify the presence of an active member of a drug class in a sample, time will not have to be spent developing a specific antibody for each member of a drug family. Additionally, information regarding patient compliance with taking medication or efficient detection of active medication in a patient's system are also possible using the present invention.

[0015] To identify the presence or level of drugs acting on specific receptors, a sample of fluid is obtained from a patient. Radiolabeled ligand, which binds to the receptor of interest, is added to the sample and the mixture is put into a test tube containing the receptor. If the sample contains a drug, which binds to the receptor, the drug will compete with the radiolabeled ligand for the receptor sites during an incubation period. After incubation, the tubes are centrifuged and decanted, leaving the membranes with bound drug and radiolabeled ligand in the tubes. Gamma counter measures the radioactive tracer activity bound to the receptors in the tube. The amount of activity is inversely proportional to the amount of unlabeled drug in the

sample. Of course, standards can also be established using methods described above so that the presence of drugs as well as levels of those drugs can be determined from any sample.

[0016] It is understood that when the term "active drug" is used herein, the term encompasses drugs, which are therapeutically active as taken as well as drugs, which have changed in structure before becoming therapeutically active. The term also encompasses metabolites that are therapeutically active. Additionally, the terms "family" and "class" are used interchangeably when referring to drugs having similar therapeutic properties.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0017] The following examples set forth preferred embodiments of the present invention. It is to be understood, however, that these examples are provided by way of illustration and nothing therein should be taken as a limitation upon the overall scope of the invention.

### EXAMPLE 1

[0018] This example tested for the presence of an ACE-inhibiting drug in a fluid sample taken from an individual by measuring enzyme inhibition in the fluid sample.

#### [0019] Materials and Methods

[0020] The synthetic pentapeptide substrate, n-(3(2-furyl)acryloyl)-L-phen- ylanaylglycylglycine(FAPGG) (Sigma Chemical Company, St Louis, Mo., Cat # 305-10) was reconstituted in a bottle with 5 ml of deionized water and left standing for five minutes. The bottle was then inverted a few times and then put on a shaker (Clay Adams CA6000 Centrifuge Becton Dickinson Microbiology System Sparks, Md.) at speed setting 2 for ten minutes. The ACE serum used for this Example was derived from a serum pool consisting of human serum samples which had been tested for ACE activity. However, it is also commercially available through Sigma as part of a kit. All samples, which had an ACE activity greater than 50 units per liter, were combined to form the ACE serum pool. This serum pool was diluted 1:4 with Tris buffer (pH 8.2, 0.136 M) and used as the enzyme source. The Tris buffer (Tris (hydroxymethyl) aminomethane, Sigma Chemical Company, Cat # 25-285-9, Lot # 27H5726 m.w.121.1) was prepared by dissolving 1.695 g Tris base in 50 ml deionized water in a 100 milliliter graduated cylinder. The pH was adjusted to 8.2 with 6 N hydrochloric acid. The stock solution for the inhibitor was 50 mM Captopril (Sigma Chemical Company, Cat #4020, Lot #37H120) that was made by dissolving 10.86 mg Captopril in 1 ml 0.136 mM Tris Buffer. A positive assay control was prepared by diluting the 50 mM Captopril stock. Ten (10) microliters of 50 mM Captopril stock was diluted with 1 milliliter of 0.136M Tris-HCL buffer, pH 8.2. The positive assay control has a normal concentration of 0.5 mM Captopril. A cut-off level of control was prepared by dilution of the 0.5 mM Captopril positive control with Tris buffer. 200 microliters of 0.5 mM Captopril was diluted with 1.8 milliliters of 0.136 M Tris buffer, pH 8.2. Finally, a negative control of Captopril was prepared by a 1:10 dilution of the cutoff control. 200 .mu.l of the 0.5 mM Captopril cutoff control was diluted with 1.8 ml of the Tris Buffer.

[0021] Using the above-described reagents, a Hamilton MicroLab AT pipetting station was used to transfer 100 .mu.l of the ACE serum in Tris buffer to each well of a microtiter plate. Next, 25 .mu.l of the cut-off level calibrator, controls and unknowns were added to their corresponding well locations with the Hamilton MicroLab AT, as shown in Table 1.

1TABLE 1 Wells A1 B1 C1 D1 E1 F1 G1 H1 Serum Control Negative Control Cutoff Positive Control Calibrator

[0022] Five different patient samples were then added to five other wells. The microtiter plate was shaker on Titer Plate Shaker (Lab Line Instruments, Inc. Melrose, Ill.) at a setting of 2 for at least five minutes before pipetting 100 .mu.l of the substrate FAPGG into each well. Next, solution was mixed by shaking the microtiter plate on the shaker at a speed setting of 2 for one minute. The microtiter plate was placed in the

Spectra Mac Plus (Molecular Devices, Sunnyvale, Calif.) plate reader and the optical density of each sample at 340 nanoMeter was determined. The microtiter plate was then incubated at 37.degree. C. for two hours. The optical density was again determined on the plate reader. This two-hour reading of optical density was then subtracted from the initial reading of optical density and termed the "delta OD 340."

[0023] For quality control purposes the positive control should have a delta OD 340 less than the delta OD 340 of the cutoff calibrator. The negative control should have a delta OD 340 which is greater than the delta OD 340 of the cutoff calibrator.

#### [0024] Results

[0025] Results for this example are given in Table 2.

2TABLE 2 Sample Initial OD 340 2 HR OD 340 Delta OD 340 ACE Serum 1151 852 299 Negative Control 1141 855 286 Cut-off Calibrator 1148 976 172 Positive Control 1172 1145 27 Unknown 1 1388 1089 299 Unknown 2 1553 1257 296 Unknown 3 1291 975 316 Unknown 4 1554 1512 42 Unknown 5 1322 1026 296

[0026] To interpret these results, the ACE inhibitor activity is inversely proportional to the delta OD 340. Therefore, a sample containing unknown amounts of ACE-inhibiting drugs is positive for ACE inhibitors if the delta OD 340 of the sample is less than the cutoff calibrator delta OD 340. Conversely, a sample containing unknown amounts of ACE-inhibiting drugs is negative for ACE inhibitors if the delta OD 340 of the sample is greater than the cutoff calibrator delta OD 340. As shown in Table 2, unknown sample number 4 has a delta OD 340 (42) which is less than the delta OD 340 of the cutoff calibrator (172). This indicates that unknown sample number 4 is positive for ACE inhibiting drugs and, therefore, ACE inhibition activity.

#### EXAMPLE 2

[0027] This example demonstrated that the assay for ACE-inhibiting drugs identified many different medications from the family of ACE-inhibiting drugs.

#### [0028] Materials and Methods

[0029] Fluid samples were obtained from individuals reporting that they were currently taking an ACE-inhibiting drug. The samples and controls were assayed as in Example 1. The medications reported by the patients included eight different medications of the ACE-inhibiting drug family. Each individual reported taking only one specific ACE-inhibiting drug. Thus, this example tests the ability of the assay to identify individuals on ACE-inhibiting drugs without prior knowledge of the specific drug being taken.

#### [0030] Results

[0031] Results from this example are given below in Table 3.

3 TABLE 3 DRUG LISTED DETECTED BENAZEPRIL 14 14 CAPTOPRIL 2 2 ENALAPRIL 5 5 FOSINOPRIL 6 5 LISINOPRIL 25 22 MOEXIPRIL 4 3 RAMIPRIL 2 2 QUINAPRIL 15 15 TOTAL 73 68

[0032] In this example, 93.1% of urine samples from individuals self-reporting ACE use tested positive for ACE-inhibiting drugs. Thus, the enzyme specific assay for the detection of therapeutic drugs works and one enzyme assay can detect all members of a drug class or family. Additionally, the assay is superior to antibody based amino assays in that no antibody needs to be produced for each drug to be tested for. In other words, the enzyme-based assay can detect all members of a drug class while an antibody-based immunoassay potentially detects only the specific drug that the antibody was developed against. Of course, the 93.1% identification rate assumes that all patients that reported taking the medications had actually taken their prescribed medications as instructed.

## EXAMPLE 3

[0033] This example provides a cell receptor assay for B1 adrenergic receptors and tests the accuracy of the assay. Patient urine that may or may not contain target ligand and a radiolabeled competitive ligand are added to a test tube containing a limited concentration of cell membrane containing beta-1-adrenergic receptors. The unlabeled ligand in the patient's urine competes with the labeled ligand for the receptor sites during an incubation period. Following incubation the tubes are centrifuged to precipitate the cell membrane-receptors. The solution containing unbound ligand is decanted and the radioactivity retained in the tubes is detected in a gamma counter. The amount of radioactivity bound is indirectly proportional to the concentration of unlabeled ligand present in the patient's urine.

## [0034] Materials and Methods

[0035] Tris working buffer (Sigma Chemical) Dissolve 4.55 grams of Tris base, 1.27 g MgCl<sub>2</sub> (hexahydrate), 0.37 g disodium dihydrate ethylenediaminetetraacetic acid, and 0.5 g ascorbic acid in 450 milliliter of deionized water. Adjust the pH to 7.4 with concentrated hydrochloric acid and fill to volume with deionized water.

[0036] Beta-1-adrenergic receptor containing membranes (Sigma Chemical #RBIB-143). Thaw the stock solution of membrane and dilute to 30 milliliter with Tris working buffer.

[0037] Radiolabeled 125-iodocyanopindolol (100 microCurries #IM142 Amersham Pharmacia Biotech Piscataway, N.J.) a stock solution of iodocyanopindolol is prepared by diluting 100 uCi of Amersham Pharmacia provided stock with 4.9 milliliter of Tris working buffer. The working solution of radiolabel is prepared by diluting the stock 1 to 30 with Tris working buffer. Drug free urine is obtained from UTAK Laboratories, Valencia, Calif. Atenolol, Propranolol, Metoprolol were from Sigma Chemical Company St. Louis, Mo. Atenolol, propranolol and metoprolol were diluted with HPLC grade ethyl alcohol (Aldrich Chemical Company Milwaukee, Wis.) to produce a 1.0 mg/ml stock solution for each drug. A cut-off control was prepared by dilution of 100 ul of stock solution of tenolol with 4.9 milliliter of UTAK drug negative urine, nominal concentration 20 ug/ml.

[0038] Samples, controls and the cut-off calibrator are diluted 1 to 10 with working buffer prior to assay. 100 microliter of Tris working buffer, 25 ul of diluted sample, cut-off calibrator, or control, 25 ul of diluted radiolabeled iodocyanopindolol, and 50 ul of working membrane solution were added to a 12.times.75 millimeter test tube. The solution was mixed by vortex and incubated for two hours at room temperature. After incubation, 1 ml of ice cold Tris working buffer was added to each tube and then centrifuged at 4,000 rpms in a Clay Adams CA6000, (Becton Dickinson Microbiological Systems Sparks, Md.) for 10 minutes. The supemate was decanted off and the tops of the tubes were blotted. The total radioactivity was detected on Packard Cobra II Auto Gamma counter (Packard Instrument Company Downers Grove, Ill.). The cut-off was calculated by multiplying the value for 20 ug/ml of Atenolol times 1.4. The calculated value is 1.4.times.5117=7164

4TABLE 2 Beta-1-adrenergic-blocker study HPLC Sample Number Counts per Minute Interpretation (Yes/No) 1 720 Positive 2 5783 Positive 3 2932 Positive 4 2769 Positive 5 5192 Positive 6 6588 Positive 7 1393 Positive 8 3244 Positive 9 5117 Cut-off atenolol 10 6026 Positive 11 1156 Positive 12 11509 Negative 13 9659 Negative 14 13884 Negative 15 7432 Negative 16 12561 Negative 17 13178 Negative 18 10502 Negative 19 6959 Positive 20 9865 Negative 21 7665 Negative 22 8706 Negative 23 8708 Negative 24 12421 Negative

[0039] All positive samples were identified correctly, while one negative (1/13) also tested positive. The overall correlation was calculated to be 95.8%.

\* \* \* \* \*

[Images](#)[Add to Shopping Cart](#)[View Shopping Cart](#)[Hit List](#)[Top](#)[Help](#)[Home](#)[Boolean](#)[Manual](#)[Number](#)[PTOLs](#)

## Case Creation Option

*Case "10037772us20060316" already exists. Please overwrite it or cancel the operation.*

### The Contents of Case "10037772us20060316"

Qnum	Query	DB Name	Thesaurus	Operator	Plural
Q1	Captopril or ("Angiotensin - Converting Enzyme inhibitor") or (ACE-inhibitor) or ("peptidyl-dipeptidase A inhibitor") or benazepril or enalapril or fosinopril or lisinopril or quinapril or moexipril or ramipril or trandolapril	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q2	(peptidyl-dipeptidase A) or ("Angiotensin converting enzyme") or (ACE) or ("EC 3.4.15.1") or ("RN-9015-82-1")	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q3	((peptidyl-dipeptidase A) or ("Angiotensin converting enzyme") or (ACE) or ("EC 3.4.15.1") or ("RN-9015-82-1")) near5 (inhibitor or modulator)	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q4	((peptidyl-dipeptidase A) or ("Angiotensin converting enzyme") or (ACE) or ("EC 3.4.15.1") or ("RN-9015-82-1")) near5 (inhibit\$7 or modulat\$3)	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q5	assay\$5 or evaluat\$6 or method or detect\$6 or determin\$7	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q6	urine or blood or serum or plasma or (body fluid)	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q7	Q1 same Q6	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q8	Q1 same Q5	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q9	Q3 same Q6	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q10	Q4 same Q6	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q11	Q5 and Q10	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES

Q12	Q5 and Q9	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q13	Q5 and Q7	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q14	Q11 and Q13	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q15	Q12 and Q14	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q16	Q1 and Q5	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q17	Q6 and Q16	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q18	activity or presence	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q19	Q5 same Q18	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q20	Q1 and Q19	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q21	Q3 and Q19	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q22	Q4 and Q19	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q23	Q20 and Q22	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q24	K21 and Q23	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q25	Q21 and Q23	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q26	Q6 and Q25	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q27	patient or human or animal or individual	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q28	Q27 and Q6	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q29	Q8 and Q28	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q30	((peptidyl-dipeptidase A) or ("Angiotensin converting enzyme") or (ACE) or ("EC 3.4.15.1") or ("RN-9015-82-1")) near5 (inhibitor)	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q31	Q30 and Q5	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q32	(human or patient or (human near5 patient)) near5 (urine or blood or serum)	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q33	Q31 and Q32	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q34	@pd<20001109 and Q33	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q35	Q1 and Q34	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q36	("RN-9041-90-1") or (Angiotensin I) or Pepsitensin or Proangiotensin	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q37	Q3 and Q36	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q38	Q32 and Q37	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES

Q39	Q1 and Q36	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q40	Q32 and Q39	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q41	Q8 and Q40	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q42	@pd<20001109 and Q41	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q43	captopril	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q44	Q5 and Q43	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q45	Q32 and Q44	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q46	Q36 and Q44	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q47	Q32 and Q46	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q48	Q45 and Q47	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q49	@pd<20001109 and Q48	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q50	determine or detect	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q51	Q50 and Q43	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q52	Q32 and Q43	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q53	Q51 and Q52	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q54	@pd<20001109 and Q53	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q55	((peptidyl-dipeptidase A) or ("Angiotensin converting enzyme") or (ACE) or ("EC 3.4.15.1") or ("RN-9015-82-1"))	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q56	Q55 and Q36	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q57	Q55 and Q32	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q58	Q36 and Q32	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q59	Q57 and Q58	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q60	Q51 and Q59	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q61	Q51 and Q32	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q62	Q60 and Q61	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q63	@pd<20001109 and Q62	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q64	(human or patient or (human near5 patient)) near5 (urine or serum)	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q65	Q50 and Q55	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q66	Q36 and Q55	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES

Q67	Q64 and Q66	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q68	Q64 and Q65	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q69	Q67 and Q68	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q70	Q18 and Q43	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q71	Q50 and Q70	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q72	Q64 and Q71	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q73	Q66 and Q72	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q74	Q69 and Q73	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q75	@pd<20001109 and Q74	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q76	(captopril or (inhibitor of angiotensin converting enzyme) or enalapril or enalaprilat or lisinopril or ramipril or ramiprila)	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q77	measure or monitor	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q78	measure or monitor or quantify or determine	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q79	Q78 and Q76	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q80	Q79 and Q64	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q81	@pd<20001109 and Q80	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q82	@py>=1998<=20001109 and Q80	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q83	@py>=1998<=2000 and Q80	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q84	@py>=1999<=2000 and Q80	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q85	Q76 same (serum or urine)	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q86	Q78 same Q76	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q87	Q85 same Q86	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q88	@py>=1999<=2000 and Q86	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q89	Q88 and @pd > 20050713	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q90	435/7.9.ccls.	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q91	Q88 and Q90	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q92	Q87 and Q90	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q93	Q78 and Q90	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q94	Q86 and Q93	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES

Q95	Q87 and Q93	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q96	Q88 and Q93	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q97	Q11 AND Q18	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q98	Q97 AND Q93	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES
Q99	Q98 AND Q76	PGPB,USPT,USOC,EPAB,JPAB,DWPI	None	ADJ	YES

---

**Overwrite****Cancel**